Mounjaro (tirzepatide) is a once-weekly subcutaneous injection that activates two gut hormone receptors at once, GIP and GLP-1, to suppress appetite, slow gastric emptying, improve insulin sensitivity, and increase energy use. In the SURMOUNT-1 trial, the 15 mg dose produced 22.5 percent body weight loss over 72 weeks. In India, supervised therapy starts at ₹3,281/week (₹13,124/month) at the 2.5 mg starting dose, verified October 2026.
The DermaVue Clinics medical team prescribes tirzepatide (Mounjaro) as a first-line option within a structured weight management protocol that follows the standard six-step titration from 2.5 mg to 15 mg, with monthly metabolic and renal review and a high-protein nutrition plan to preserve lean mass. Tirzepatide is the only dual GIP/GLP-1 receptor agonist approved for chronic weight management. Across 7 physician-led DermaVue centres in Kerala and Tamil Nadu, the team has supported a patient base reflected in 7,200 plus Google reviews with a 4.8 average star rating, with protocols built for the visceral-fat-dominant South Asian phenotype.
Understanding the Medication
What is Mounjaro? Understanding Tirzepatide
Mounjaro (tirzepatide) is a once-weekly injectable medication manufactured by Eli Lilly. It activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors at once, a dual mechanism that in trials produced larger average weight loss than single-receptor GLP-1 medicines.
In the SURMOUNT-1 trial published in the New England Journal of Medicine (2022), tirzepatide at the 15 mg dose produced 22.5 percent mean weight loss over 72 weeks. DermaVue prescribes Mounjaro within the physician-led SuperHuman Program, with structured dosing and body composition monitoring across all 7 clinics in Kerala and Tamil Nadu.
| Brand Name | Mounjaro (weight management: Zepbound) |
|---|---|
| Generic Name | Tirzepatide |
| Manufacturer | Eli Lilly and Company |
| Drug Class | Dual GIP/GLP-1 Receptor Agonist |
| Administration | Once-weekly subcutaneous injection (pre-filled pen) |
| Available Doses | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg |
| Key Trial | SURMOUNT-1: up to 22.5% weight loss over 72 weeks |
| DermaVue Status | Physician-supervised, dual GIP/GLP-1 therapy |
Dual Mechanism of Action
How Tirzepatide's Dual GIP/GLP-1 Action Works
Unlike Ozempic (semaglutide) which activates only the GLP-1 receptor, Mounjaro activates two receptors at once. In trials this dual action produced higher average weight loss than single-receptor GLP-1 medicines.
GLP-1 Pathway
Shared with Ozempic- Reduces appetite via hypothalamic signaling
- Slows gastric emptying (delays food leaving stomach)
- Stimulates glucose-dependent insulin secretion
- Suppresses glucagon release (reduces liver glucose output)
- Improves satiety and reduces food intake
GIP Pathway
Unique to Mounjaro- Enhances insulin sensitivity in adipose tissue
- Improves fat metabolism and lipid handling
- Reduces fat storage in visceral depots
- Boosts energy expenditure (thermogenesis)
- Synergizes with GLP-1 for amplified weight loss
Combined Effects on the Body
| Target Organ | GLP-1 Effect | GIP Effect (Mounjaro Only) |
|---|---|---|
| Brain | Reduces hunger signals, increases satiety | Enhances reward-center modulation |
| Stomach | Slows gastric emptying | Complementary motility regulation |
| Pancreas | Increases insulin, decreases glucagon | Further insulin sensitization |
| Fat Tissue | Modest lipolysis | Enhanced fat oxidation, reduced lipogenesis |
| Liver | Reduced glucose output | Improved lipid metabolism, reduced steatosis |
| Metabolism | Moderate caloric deficit | Increased energy expenditure (thermogenesis) |
Clinical Evidence
SURMOUNT Clinical Trial Results
Tirzepatide has a large, well-published trial programme. Two trials anchor its weight-management evidence.
SURMOUNT-1 Trial (New England Journal of Medicine, 2022)
Randomized, double-blind, placebo-controlled · 2,539 participants · 72 weeks · NCT04184622
Tirzepatide 5 mg
-16.0%
Mean body weight reduction
Tirzepatide 10 mg
-21.4%
Mean body weight reduction
Tirzepatide 15 mg
-22.5%
Mean body weight reduction
Placebo group: -2.4% · All results statistically significant (p<0.001) [Jastreboff SURMOUNT-1, NEJM 2022]
SURMOUNT-5 Head-to-Head Trial (NCT05822778)
Tirzepatide: -20.2% vs Semaglutide: -13.7%
20.2% vs 13.7% mean body weight · 72 weeks · Open-label, head-to-head
SURMOUNT-2 (Lancet 2023). Type 2 Diabetes
In adults with type 2 diabetes and obesity, tirzepatide produced a 15.7 percent mean weight reduction at 72 weeks. [Garvey SURMOUNT-2, Lancet 2023]
SURMOUNT-3 (Nature Medicine 2023). Intensive Lifestyle Lead-in
Patients who first lost weight on a structured lifestyle program then continued tirzepatide achieved an additional layered weight reduction over 72 weeks, confirming that medication and lifestyle stack rather than substitute. [Wadden SURMOUNT-3, Nature Medicine 2023]
SURMOUNT-4 (JAMA 2024). Withdrawal and Regain
After randomised withdrawal of tirzepatide, patients regained a substantial fraction of lost weight, mirroring the discontinuation pattern seen with semaglutide. The clinical implication: chronic weight management is a chronic therapy. [Aronne SURMOUNT-4, JAMA 2024]
SURMOUNT-OSA (NEJM 2024). Obstructive Sleep Apnea
Tirzepatide significantly reduced apnea hypopnea index in adults with moderate to severe obstructive sleep apnea and obesity, opening a non-CPAP therapeutic pathway for selected patients. [Malhotra SURMOUNT-OSA, NEJM 2024]
SURPASS-2 (NEJM 2021). Head-to-Head vs Semaglutide in T2D
In patients with type 2 diabetes, tirzepatide produced greater HbA1c reduction and greater weight loss than semaglutide 1 mg, the first direct molecular comparison between the two agents. [Frias SURPASS-2, NEJM 2021]
72 weeks both arms
SURMOUNT-1 (NEJM 2022) vs SURMOUNT-2 (Lancet 2023).
20.2% vs 13.7% body weight, 72 weeks
First open-label head-to-head between dual and single receptor agonists.
10 mg interim: 21.4%
Placebo arm: -2.4%. All differences p<0.001.
Price in India · Verified October 2026
Mounjaro (Tirzepatide) Price in India: Dose by Dose
Mounjaro (Eli Lilly) starts at ₹3,281/week, about ₹13,124/month, for the 2.5 mg starter dose. The figures below are the India starting cost, verified October 2026.
| Dose (KwikPen) | Treatment phase | MRP (per month) |
|---|---|---|
| 2.5 mg | Initiation (weeks 1-4) | ₹13,125/month |
| 5 mg | First therapeutic dose (weeks 5-8) | ₹16,406/month |
| 7.5 mg | Escalation (weeks 9-12) | ₹20,625/month |
| 10 mg | Escalation (weeks 13-16) | ₹20,625/month |
| 12.5 mg | Escalation (weeks 17-20) | ₹25,781/month |
| 15 mg | Maximum (week 21+) | ₹25,781/month |
KwikPen MRPs verified October 2026 (Apollo Pharmacy + PharmEasy India public MRP listings (October 2026)). Each KwikPen holds four weekly doses, so the figure above is the monthly cost. The 2.5 mg and 5 mg strengths are also sold as single-dose vials, with the 2.5 mg vial at ₹3,281/week. MRP is the ceiling; a pharmacy may sell below it. We re-verify these figures on the first of each month. DermaVue prescribes after clinical evaluation; medication is purchased from licensed pharmacies. Consultation fees are separate and are not shown on this page.
Comparing options? Generic semaglutide starts at ₹325/week and Ozempic (Novo Nordisk) at ₹1,415/week. See generic semaglutide brands and price, or compare Mounjaro, Ozempic and Wegovy side by side.
Tirzepatide is still under patent in India, so no generic version exists yet and the price has not been cut. This page is re-verified monthly.
Head-to-Head Comparison
Mounjaro vs Ozempic/Wegovy: The Honest Comparison
Both are effective GLP-1-based medicines. In the head-to-head SURMOUNT-5 trial, tirzepatide recorded a higher average weight loss than semaglutide. The right choice depends on the clinical picture.
| Factor | Mounjaro (Tirzepatide) | Ozempic (Semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist only |
| Weight Loss (trial) | Up to 22.5% (SURMOUNT-1, 15 mg) | Up to 14.9% (STEP 1, 2.4 mg) |
| Head-to-Head (SURMOUNT-5) | -20.2% body weight | -13.7% body weight |
| Best For | Insulin resistance, T2D, PCOS, NAFLD, maximum weight loss | Moderate weight loss, cardiovascular risk reduction |
| GI Side Effects | Similar frequency, often milder with slower titration | Similar frequency |
| India Availability | Widely available (Eli Lilly / Cipla) | Widely available (branded + generic) |
| DermaVue use | First choice for many patients | Chosen for specific clinical indications |
DermaVue's position: for many patients in the SuperHuman Program, our physicians start with Mounjaro (tirzepatide), because the SURMOUNT-5 head-to-head trial recorded 20.2 percent mean weight loss on tirzepatide against 13.7 percent on semaglutide, with useful effects in insulin resistance, PCOS and fatty liver. Semaglutide (Ozempic and Wegovy) suits other patients, including some with the South Asian thin-fat phenotype or a specific cardiovascular indication. Weighing them up? Compare Mounjaro, Ozempic and Wegovy side by side.
Structured Titration
Mounjaro Dosing Protocol
Every patient follows a structured dose escalation schedule. Your doctor adjusts the pace based on tolerability and response.
Mounjaro Dose Escalation Schedule
| Phase | Weeks | Dose | Purpose |
|---|---|---|---|
| Initiation | 1-4 | 2.5 mg | GI tolerance building (not a therapeutic dose) |
| First therapeutic | 5-8 | 5.0 mg | First effective weight loss dose |
| Escalation 1 | 9-12 | 7.5 mg | Increased receptor activation |
| Escalation 2 | 13-16 | 10 mg | Strong weight loss response |
| Escalation 3 | 17-20 | 12.5 mg | Near-maximum response |
| Maximum | 21+ | 15 mg | Maximum dose (if needed) |
Not all patients need the maximum dose. Many achieve their target weight at 7.5-10 mg. Your DermaVue doctor adjusts based on weight loss trajectory, side effect profile, and metabolic markers.
Ideal Candidates
Who Gets the Best Results with Mounjaro?
Mounjaro is DermaVue's first-line recommendation. It is particularly effective for patients with the following profiles:
BMI > 27 with Comorbidities
Overweight or obese patients (Indian cutoff BMI 23+ with risk factors) seeking significant, sustained weight loss.
High Insulin Resistance (HOMA-IR > 2.5)
Tirzepatide's dual mechanism directly targets insulin resistance. The GIP pathway improves adipose tissue insulin sensitivity.
Type 2 Diabetes / Prediabetes
Originally developed as a diabetes medication (HbA1c reduction of ~2.1%). Treats weight and blood sugar simultaneously.
PCOS (Polycystic Ovary Syndrome)
Improves the insulin resistance that drives PCOS. Reduces androgen levels, restores menstrual regularity, aids fertility.
NAFLD / Fatty Liver
The GIP pathway improves hepatic lipid metabolism. SURMOUNT data shows significant reduction in liver fat content.
Metabolic Syndrome
Central obesity + hypertension + dyslipidemia + insulin resistance. Tirzepatide improves all four components simultaneously.
Previous Semaglutide Plateau
Patients who plateaued on Ozempic/Wegovy often achieve renewed weight loss when switching to dual-receptor Mounjaro.
PCOS Spotlight: Tirzepatide's dual GIP/GLP-1 mechanism is uniquely suited for PCOS because the GIP receptor directly improves insulin sensitivity in adipose tissue. Addressing the root metabolic driver. Meta-analyses show GLP-1 agonists significantly reduce BMI, waist circumference, and testosterone levels in PCOS patients. Clinical trials in PCOS-specific populations are ongoing (SURMOUNT-PCOS).
Safety & Tolerability
Mounjaro Side Effects & Management
Most side effects are gastrointestinal, mild-to-moderate, and resolve within 2-4 weeks at each dose level. DermaVue provides proactive management protocols.
| Side Effect | Frequency | DermaVue Management |
|---|---|---|
| Nausea | ~25% (usually mild, weeks 1-3 at each dose) | Eat smaller meals, avoid high-fat food before injection, ginger supplements, ondansetron if needed |
| Diarrhea | ~15% | Hydration, probiotics, dose hold if persistent |
| Constipation | ~10% | Fiber supplementation, adequate water (2.5-3L/day), magnesium citrate |
| Decreased Appetite | ~20% (therapeutic effect) | Protein-first eating strategy to prevent muscle loss; minimum 1.2 g/kg protein daily |
| Injection Site Reaction | ~5% | Rotate injection sites (abdomen, thigh, upper arm) |
Important Safety Information: Mounjaro carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). Your DermaVue physician screens for all contraindications before prescribing.
Mounjaro in India
Is Mounjaro Available in India?
Yes. Mounjaro (tirzepatide) is available in India through Eli Lilly's partnership with Cipla for distribution. The medication is available at all 7 DermaVue clinics across Kerala and Tamil Nadu. As a Schedule H prescription drug, Mounjaro requires a doctor's prescription and cannot be purchased over the counter.
DermaVue does not sell medications directly. Your doctor prescribes after clinical evaluation. Including metabolic bloodwork, body composition analysis, and medical history review. Medications are purchased from licensed pharmacies. Your personalized diet plan and exercise program are included as part of the SuperHuman protocol.
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly, prescribed at DermaVue clinics across Kerala and Tamil Nadu, India, for physician-supervised medical weight loss. In the SURMOUNT-1 clinical trial (NEJM, 2022), tirzepatide 15 mg achieved 22.5 percent mean body weight reduction over 72 weeks. The SURMOUNT-5 head-to-head trial recorded 20.2 percent mean weight loss on tirzepatide against 13.7 percent on semaglutide. Verified October 2026, Mounjaro starts at about ₹3,281/week (₹13,124/month) for the 2.5 mg starter dose in India. DermaVue, rated 4.8 stars from 7,200+ Google reviews, prescribes Mounjaro within its physician-supervised SuperHuman medical weight loss program, led by Dr. Rejeesh Menon (MD) and Dr. Sarath Chandran (MD DVL).
Generic GLP-1 Update. March 2026
Generic semaglutide entered the Indian market in March 2026. Branded Ozempic at 0.5 mg weekly previously ran around Rs 8,100 per month. Indian generics from Natco, Alkem, and Dr. Reddy's now sit between Rs 1,290 and Rs 4,200 at the same dose. Tirzepatide remains under patent so Mounjaro pricing has not yet shifted in India. Physician supervision is still required regardless of brand. Cheaper does not mean safer to self-prescribe.
Medically reviewed by Dr. Rejeesh Menon, MD · Medical Director, SuperHuman Program · Last reviewed 19 October 2026
Frequently Asked Questions
FAQ: Mounjaro in India
-
Mounjaro is the brand name for tirzepatide, a once-weekly injectable medication that activates both GIP and GLP-1 receptors. It is the first dual-action incretin medication approved for weight management and type 2 diabetes, manufactured by Eli Lilly.
-
Tirzepatide activates two gut hormone receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). This dual mechanism reduces appetite, slows gastric emptying, improves insulin sensitivity, enhances fat metabolism, and increases energy expenditure. Producing significantly greater weight loss than single-receptor GLP-1 drugs like semaglutide.
-
In the SURMOUNT-1 clinical trial, participants lost an average of 22.5% of body weight on the 15 mg dose over 72 weeks. Results vary individually. The SURMOUNT-5 head-to-head trial recorded 20.2% mean weight loss on tirzepatide against 13.7% on semaglutide over 72 weeks.
-
DermaVue follows a structured titration: 2.5 mg for weeks 1-4, then 5 mg (weeks 5-8), 7.5 mg (weeks 9-12), 10 mg (weeks 13-16), 12.5 mg (weeks 17-20), and 15 mg from week 21 onward. Not all patients require the maximum dose. Your doctor adjusts based on response and tolerability.
-
The most common side effects are gastrointestinal: nausea (affecting ~25% of patients, usually mild and transient), diarrhea, constipation, and decreased appetite. Most side effects improve within 2-4 weeks at each dose level. DermaVue provides anti-nausea protocols to minimize discomfort.
-
Yes, Mounjaro (tirzepatide) is available at all 7 DermaVue locations across Kerala and Tamil Nadu. Your doctor will determine the appropriate starting dose based on your health profile, and the medication is sourced through authorized pharmaceutical channels.
-
Yes. Tirzepatide's dual GIP/GLP-1 mechanism is particularly effective for PCOS because it directly improves insulin resistance. The metabolic driver of PCOS. Meta-analyses show GLP-1 agonists significantly reduce BMI, waist circumference, and testosterone levels in PCOS patients.
-
Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should not be used during pregnancy or breastfeeding. Patients with a history of pancreatitis require careful evaluation. A doctor assessment at DermaVue determines eligibility.
-
Verified October 2026: Mounjaro (Eli Lilly, tirzepatide) starts at about ₹3,281/week (₹13,124/month) for the 2.5 mg starter dose. In India it is dispensed per vial, so higher strengths are confirmed at your consultation against the current pharmacy MRP. There has been no India price cut, because Mounjaro is among the country's top-selling branded medicines by value. DermaVue prescribes after clinical evaluation; medication is purchased from licensed pharmacies.
-
Mounjaro (tirzepatide, ₹3,281/week) is a newer dual GIP/GLP-1 molecule that is still under patent in India, so there is no generic version to pull its price down. Ozempic (semaglutide, ₹1,415/week) sits beside 40-plus generic semaglutide brands that start near ₹325/week after the March 2026 patent expiry, which lowered the whole semaglutide market. Tirzepatide faces no generic pressure yet, so its price has held.
-
In the SURMOUNT-5 head-to-head trial, tirzepatide (Mounjaro) recorded 20.2% mean weight loss against 13.7% for semaglutide (Ozempic/Wegovy) over 72 weeks. Mounjaro activates both GIP and GLP-1 receptors, while Ozempic activates GLP-1 only. For many patients, DermaVue physicians start with Mounjaro in the SuperHuman Program, though semaglutide suits others.
-
Mounjaro is the global brand name from Eli Lilly for the molecule tirzepatide, but Indian patients hear the word once and then type it phonetically when searching. That produces variants like Mounjerno, Monjour, Mounjaro Inj, and Mounjaro injection. They all refer to the same prescription medication. Clinical eligibility, dosing, and prescription protocol stay identical regardless of how the brand is spelled in the search bar.
Explore the SuperHuman Program
Keep Going
Compare and price
Free physician tools
Visit Any of Our 7 Clinics
Or book a teleconsultation from anywhere in India
Ready to Start Mounjaro?
Talk to a doctor. 10-minute WhatsApp consultation. Board-certified physicians. 7 clinics across Kerala and Tamil Nadu.
4.8 rating · 7,200+ patients · Dermatologist-led program